Terms and Conditions
Terms and conditions of the use of EFCG web site. These conditions may be changed at any time.
The material contained on this web site is for information only. EFCG endeavours to make its best efforts to up-date the information on a regular basis, but it is not claimed to be exhaustive. EFCG has compiled the pages on this web site very carefully, and the information placed on this web site is offered in utmost good faith.
This information is believed to be correct. Nevertheless, EFCG makes no representations or warranties as to the completeness or accuracy of any of this information.
EFCG will in no event be responsible for damages of any nature whatsoever resulting from the use or reliance to the information contained in this web site.
This site and its content, where applicable, are subject to the copyright of EFCG. Reproduction is authorised, except for commercial purposes, provided that the source is mentioned and acknowledged.
EFCG claims no copyright on any official document or in the public domain. Copyright, if any, of third party material found in this site must also be respected.
Links to other web sites are provided solely as a convenience. Therefore, those links imply neither responsibility for, nor approval of, the information contained in these web sites by EFCG.
In 2004 EFCG raised the first red flags about sub-standard Active Pharmaceutical Ingredients (APIs) entering Europe from India and China. Twelve years on, it appears that risks to patients from non-compliant bad quality APIs have been substantially reduced and that the playing field is levelling out.
EFCG Press Conference CPhI 2015: "API" day for Europe as Big Pharma returns in search of quality (by Dan Stanton)
EFCG Press Conference CPhI 2015: Outlook in Europe for API Manufacturers is positive, says EFCG